Sarepta Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $442,934 | $399,356 | $611,091 | $744,856 |
Gross Profit | 44,226 | 248,581 | 458,533 | 607,292 |
EBITDA | -252,199 | -168,034 | 169,706 | -369,037 |
EBIT | -257,452 | -186,484 | 158,866 | -379,015 |
Net Income | -282,847 | -179,947 | 196,892 | -447,508 |
Net Change In Cash | 442,934 | 399,356 | 611,091 | 744,856 |
Free Cash Flow | 125,377 | -42,831 | 229,353 | -629,326 |
Cash | 801,282 | 613,077 | 510,598 | 240,867 |
Basic Shares | 104,793 | 100,237 | 106,623 | 97,362 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,198,237 | $1,901,979 | $1,243,336 | $933,013 |
Gross Profit | 1,316,733 | 1,582,880 | 1,092,993 | 793,024 |
EBITDA | -647,973 | 316,889 | -453,691 | -594,851 |
EBIT | -692,494 | 279,165 | -498,088 | -636,715 |
Net Income | -713,410 | 235,239 | -535,977 | -703,488 |
Net Change In Cash | 2,198,237 | 1,901,979 | 1,243,336 | 933,013 |
Free Cash Flow | -307,451 | -352,743 | -588,338 | -357,597 |
Cash | 801,282 | 1,103,010 | 428,430 | 966,777 |
Basic Shares | 104,793 | 107,875 | 92,398 | 87,559 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$3.58 |
2025-09-30 | -$0.13 |
2025-06-30 | $2.02 |
2025-03-31 | -$3.42 |
